New executive appointment at Elan
This article was originally published in Scrip
Elan has named Dr Eliseo Oreste Salinas executive vice-president and chief medical officer, with responsibility for leading the company's development, clinical and medical initiatives. He will be based at the company's South San Francisco campus and will report to its president, Dr Carlos Paya. As chief medical officer, he will also retain specific accountabilities to the Elan's CEO, Kelly Martin, relating to patient safety. Dr Salinas joins from Adolor, where he was senior vice-president of R&D and chief medical officer. Before that, he was at Shire, where he worked as chief scientific officer and executive vice-president of global pharmaceutical R&D. Elan's current chief medical officer and head of development, Dr Menghis Bairu, will resume his primary responsibility as executive vice-president and general manager of Tysabri.
You may also be interested in...
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.